Last reviewed · How we verify
Phentermine / Topiramate Oral Product
Phentermine / Topiramate Oral Product is a Sympathomimetic amine / Anticonvulsant combination Small molecule drug developed by University of Florida. It is currently in Phase 3 development for Chronic weight management in obese or overweight patients with weight-related comorbidities. Also known as: Duromine, Adipex-P, Lomaira, Suprenza.
Phentermine acts as a sympathomimetic amine to suppress appetite, while topiramate enhances satiety and may increase metabolic rate through multiple mechanisms including carbonic anhydrase inhibition.
Phentermine acts as a sympathomimetic amine to suppress appetite, while topiramate enhances satiety and may increase metabolic rate through multiple mechanisms including carbonic anhydrase inhibition. Used for Chronic weight management in obese or overweight patients with weight-related comorbidities.
At a glance
| Generic name | Phentermine / Topiramate Oral Product |
|---|---|
| Also known as | Duromine, Adipex-P, Lomaira, Suprenza, Trokendi XR |
| Sponsor | University of Florida |
| Drug class | Sympathomimetic amine / Anticonvulsant combination |
| Target | Norepinephrine release (phentermine); carbonic anhydrase inhibition and GABA modulation (topiramate) |
| Modality | Small molecule |
| Therapeutic area | Obesity / Weight Management |
| Phase | Phase 3 |
Mechanism of action
Phentermine is a sympathomimetic amine that stimulates the release of norepinephrine in the hypothalamus, reducing appetite and increasing energy expenditure. Topiramate is an anticonvulsant that enhances weight loss through multiple mechanisms including increased satiety, reduced appetite, and potential metabolic effects. The combination produces synergistic weight loss effects beyond either agent alone.
Approved indications
- Chronic weight management in obese or overweight patients with weight-related comorbidities
Common side effects
- Insomnia
- Dry mouth
- Paresthesia
- Cognitive impairment / memory issues
- Tachycardia
- Constipation
- Dizziness
Key clinical trials
- Phentermine/Topiramate for Uric Acid Stones (PHASE3)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity (PHASE2)
- Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity (PHASE2)
- EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial (PHASE4)
- Individualized Obesity Pharmacotherapy (PHASE3)
- Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phentermine / Topiramate Oral Product CI brief — competitive landscape report
- Phentermine / Topiramate Oral Product updates RSS · CI watch RSS
- University of Florida portfolio CI
Frequently asked questions about Phentermine / Topiramate Oral Product
What is Phentermine / Topiramate Oral Product?
How does Phentermine / Topiramate Oral Product work?
What is Phentermine / Topiramate Oral Product used for?
Who makes Phentermine / Topiramate Oral Product?
Is Phentermine / Topiramate Oral Product also known as anything else?
What drug class is Phentermine / Topiramate Oral Product in?
What development phase is Phentermine / Topiramate Oral Product in?
What are the side effects of Phentermine / Topiramate Oral Product?
What does Phentermine / Topiramate Oral Product target?
Related
- Drug class: All Sympathomimetic amine / Anticonvulsant combination drugs
- Target: All drugs targeting Norepinephrine release (phentermine); carbonic anhydrase inhibition and GABA modulation (topiramate)
- Manufacturer: University of Florida — full pipeline
- Therapeutic area: All drugs in Obesity / Weight Management
- Indication: Drugs for Chronic weight management in obese or overweight patients with weight-related comorbidities
- Also known as: Duromine, Adipex-P, Lomaira, Suprenza, Trokendi XR
- Compare: Phentermine / Topiramate Oral Product vs similar drugs
- Pricing: Phentermine / Topiramate Oral Product cost, discount & access